Breast metastasis is the hematogenous spread of an extra-mammary (non-breast origin) primary tumor to the breast. It constitutes 0.5-2% of all breast malignancies. The most common primary tumors are melanoma, lung carcinoma, contralateral breast carcinoma, lymphoma/leukemia, ovarian carcinoma, and renal cell carcinoma. On imaging, it generally appears as a well-defined, round, superficially located (subcutaneous fat or upper dermal layers) mass — deep parenchymal location is less common. Spiculated margins, calcification, and architectural distortion are typically absent (benign-like morphology). Multifocal/multicentric involvement may occur. Clinical history (known extra-mammary malignancy) is critically important for diagnosis. BI-RADS 4-5 classification with biopsy is required. Treatment is directed at the primary tumor.
Age Range
40-80
Peak Age
60
Gender
Female predominant
Prevalence
Rare
Metastasis to the breast occurs hematogenously — tumor cells entering circulation from the primary tumor reach breast tissue via arterial blood flow. The rich vascular structure of the breast provides a suitable environment for metastatic seeding. The preference for superficial (subcutaneous) location results from the richness of the superficial vascular plexus of the breast — circulating tumor cells first lodge in this superficial vascular network. The well-defined appearance on imaging results from metastatic cells not interacting with surrounding breast stroma — unlike primary breast carcinomas, they do not create desmoplastic stromal reaction because tumor cells are foreign to the stromal signaling pathways of breast tissue. Therefore spiculated margins and architectural distortion are absent. Absence of calcification results from metastatic tumors not being associated with ductal structures — calcification in primary breast carcinomas is related to ductal secretion and necrosis. Melanoma metastases are frequently hypervascular (melanoma has high neoangiogenesis capacity), lung metastases are less vascular. Multifocal involvement results from hematogenous spread being able to reach multiple sites simultaneously.
In a patient with known extra-mammary malignancy history, a superficially located, well-defined, round, hypoechoic solid mass in subcutaneous fat — unlike primary breast carcinomas, spiculated margins, calcification, and architectural distortion are absent. This combination (superficial location + benign morphology + malignancy history) is a strong diagnostic clue for metastasis.
Well-defined, round or oval, hypoechoic mass — usually superficially located in subcutaneous fat. Margins are smooth and well-delineated. Internal echoes may be homogeneous (melanoma) or heterogeneous (necrosis in large metastases). Posterior acoustic enhancement is prominent in melanoma metastases (hypervascularity). Spiculated margins are typically absent. Parallel orientation is expected.
Report Sentence
On US, a ___ x ___ mm well-defined, round, hypoechoic solid mass in subcutaneous location is seen in the ___ quadrant of the right/left breast; considering known ___ malignancy history, this may be consistent with metastasis.
Round, well-defined or partially defined dense mass on mammography. No calcification. No architectural distortion or spiculated margins. Halo sign may be visible (pushing growth). May be occult in dense breast tissue. Multifocal masses strongly suggest metastasis.
Report Sentence
On mammography, a ___ x ___ mm well-defined, round, dense mass is seen in the ___ quadrant of the right/left breast without calcification or architectural distortion; metastasis should be considered in the context of known malignancy history.
Enhancement pattern on contrast-enhanced MRI varies depending on primary tumor type. Melanoma metastases: intense, homogeneous enhancement and pre-contrast T1 hyperintensity (paramagnetic effect of melanin). Lung carcinoma metastases: heterogeneous enhancement, rim enhancement may be present. Kinetic curve is variable — Type II or Type III pattern. Diffusion restriction and low ADC values are expected on DWI.
Report Sentence
On contrast-enhanced MRI, the ___ x ___ mm mass in the ___ quadrant of the right/left breast shows intense/heterogeneous enhancement with/without pre-contrast T1 hyperintensity; may be consistent with known ___ metastasis.
Doppler findings vary by primary tumor type. Melanoma metastases: prominent hypervascularity, irregular intratumoral vascular flows — reflecting melanoma's high neoangiogenesis capacity. In lung and other epithelial carcinomas: moderate or peripheral vascularity. In metastases from hematologic malignancies (lymphoma/leukemia): variable vascularity.
Report Sentence
Prominent intratumoral vascularity/minimal vascularity is observed in the lesion on Doppler examination, evaluated according to primary tumor type.
FDG-avid breast mass on PET-CT — evaluated as part of systemic disease. SUVmax depends on primary tumor type. Melanoma shows high uptake, lung shows variable uptake. PET-CT is used to simultaneously assess primary tumor status, other metastatic sites, and treatment response.
Report Sentence
The ___ mm mass in the ___ quadrant of the right/left breast shows FDG uptake on PET-CT (SUVmax: ___); consistent with breast metastasis of known ___ disease.
Criteria
Most common extra-mammary tumor metastasizing to the breast. Very high hematogenous spread capacity.
Distinct Features
Pre-contrast T1 hyperintensity on MRI (paramagnetic effect of melanin) — diagnostic clue. Hypervascularity, intense enhancement. Prominent posterior enhancement on US. May be multifocal.
Criteria
Second most common type. From small cell and non-small cell lung carcinomas.
Distinct Features
Usually solitary mass. Heterogeneous enhancement may be present. Not as hypervascular as melanoma. Concurrent lung lesion/pleural effusion/mediastinal LAP is informative.
Criteria
Hematogenous spread of contralateral breast carcinoma. Can be synchronous or metachronous.
Distinct Features
Differentiation from new primary breast carcinoma is critical — immunohistochemistry (ER/PR/HER2 profile comparison) is diagnostic. Superficial location and well-defined morphology favor metastasis; spiculated margin is new primary.
Distinguishing Feature
Primary IDC typically shows spiculated margins, architectural distortion, calcification, and is deep parenchymal. Metastasis is well-defined, round, superficial, and without calcification. Immunohistochemistry (breast origin markers: GATA3, mammaglobin, GCDFP-15) is distinguishing.
Distinguishing Feature
Lymphoma also appears as well-defined hypoechoic mass but is generally larger, more homogeneous, and may be bilateral. Axillary LAP is more prominent. Melanin T1 hyperintensity is absent in lymphoma. Biopsy + immunohistochemistry is diagnostic.
Distinguishing Feature
Fibroadenoma is a well-defined, oval, homogeneous hypoechoic mass in young age — but no known malignancy history, slow growth, and superficial location is not expected. Clinical history and age are the most important distinguishing factors.
Urgency
urgentManagement
medicalBiopsy
NeededFollow-up
specialist-referralBreast metastasis indicates systemic disease and treatment approach is completely different from primary breast carcinoma — mastectomy or breast-conserving surgery is not indicated. Histopathological confirmation with core biopsy is required. Immunohistochemistry is mandatory to confirm primary tumor type and differentiate from primary breast carcinoma (breast origin markers: GATA3, mammaglobin, GCDFP-15 — if negative, non-breast origin is considered). Treatment is directed at the primary tumor (chemotherapy, targeted therapy, immunotherapy). Oncology consultation and staging are required.
Breast metastasis diagnosis must be confirmed by biopsy. Immunohistochemistry is critical for determining the primary tumor. Treatment is directed at the primary malignancy. Prognosis is generally poor as it indicates disseminated disease.